US-based Arena Pharmaceuticals has started dosing patients in an investigational Phase Ib clinical trial of APD334, an oral drug candidate...
Read moreAs of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs...
Read moreUS-based Boston Therapeutics (BTI) has started a Phase IIb clinical trial SD-002 to evaluate the efficacy and safety of Sugardown...
Read moreProvence Technologies acquires SynprosisThe acquisition strengthens Provence Technologies’ expertise in its core business of therapeutic chemistry Provence Technologies Group, a...
Read moreThe Orphan Drugs Market is set to Rise as a Result of Pharma Companies now Looking to Orphan Drugs as...
Read morePolyplus-transfection SA, a privately-held company specializing in the development of innovative solutions for transfection, today announces the launch of FectoPRO(TM),...
Read moreDenmark-based biotechnology firm Bavarian Nordic has dosed first patient in a randomised, prospective Phase II trial of its active immunotherapy...
Read moreEli Lilly has obtained US Food and Drug Administration approval for its Cyramza (ramucirumab) as a single-agent treatment for patients...
Read moreUS-based biopharmaceutical firm AbbVie has started a global Phase III clinical trial of an investigational oral poly (adenosine diphosphate -ribose)...
Read moreA Phase IIa clinical study will test the efficacy, safety and tolerability profile Ferrer, a privately-held Spanish pharmaceutical company, today announces...
Read morePharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.
© 2017 Copyright © Valuemediaservices 2017 All rights reserved.